Falmiran is the earliest enterprise engaged in packaging material compatibility in China, with more than 10 years of compatibility research experience, and has passed the on-site review of many pharmaceutical enterprises across the country. Assist many customers to complete the compatibility study of direct contact parts of various injection, powder injection, inhalation spray, eye drops and other dosage forms. At the end of 2021, Falmiran was selected as the research unit of the general test method for the sealing of packaging materials standard by the National Pharmacopoeia Commission.

Examples of completed projects:

Remazolam besylate for injection (Class 1 chemical drug, approved for production)

Remifentanil hydrochloride for injection (supplementary application, approved)

Cefotaxime sodium for injection (supplementary application, under review)

Recombinant pudk-hgf plasmid injection (approved for clinical use)

Recombinant plasmid hepatocyte growth factor injection (approved for clinical use)

Paroxycoxib sodium for injection and the drug substance Paroxycoxib sodium (TGA) (supplementary application, approved)

Omeprazole sodium for injection (supplementary application, approved)

Remifentanil hydrochloride for injection (supplementary application, approved)

Remifentanil hydrochloride for injection (supplementary application, approved)

Remifentanil hydrochloride for injection (supplementary application, approved)

Euonymol dehydrated for injection (supplementary application, accepted)

Remifentanil hydrochloride for injection (supplementary application, approved)

Xueshuantong for injection (freeze-dried) (supplementary application, under review)

Tranexamic acid for injection (supplementary application, under review)